Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery (NCT01612351), a na phase 2 study. The primary outcome is Overall Response Rate.

2. Clinical Question

The study’s stated purpose was to evaluate a three-part, risk-adapted strategy involving induction chemotherapy, transoral surgery, and radiation chemotherapy, with the aim of lessening toxic effects and improving treatment. That statement describes the study’s motivation, not a finding. The primary endpoint focused on tumor response after induction treatment; it was not itself a measure of toxicity, survival, or voice and swallowing function. Those topics appear among the listed secondary outcomes, but their observed results are not reported in the registry record.

3. Trial Design

This was a phase 2, completed, non-randomized, single-group study with an enrollment of 40. Allocation is listed as not applicable, and masking is listed as none. Participants were planned to receive induction chemotherapy and transoral surgery. Following surgery, the treatment plan used low-, medium-, and high-risk categories to guide subsequent care. The registry record lists carboplatin, paclitaxel, lapatinib, cisplatin, radiation, and transoral surgery among the interventions. It does not fully specify the post-surgical treatment assigned to each risk category in the available arm description.

The primary outcome was overall response rate, recorded as a count of participants, with an 11-week timeframe. Its description places imaging assessment at 3-5 weeks after induction chemotherapy. The registry record also lists secondary outcomes covering feasibility, change in risk level after induction chemotherapy, overall and progression-free survival, voice and swallowing function, pathologic complete response, and response at the primary site. It identifies 12 outcome measures, but does not report analysis records for these outcomes.

Enrollment began in 2012-06, primary completion was 2016-11, and the study status is completed. These are study-record milestones; they do not indicate that all planned analyses or results are available. The registry record does not report a randomized comparator, a statistical analysis plan, or the complete category-specific treatment schedules. The single-group design is central to interpreting the findings: observations can describe participants who entered this treatment strategy, but there is no concurrent control group for estimating a comparative treatment effect.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Chemotherapy

Transoral Surgery

Post-Operative Treatment

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Overall Response Rate, measured over 11 weeks.

The primary endpoint is overall response rate, defined in the registry record as the number of participants with either a complete response or a partial response. The outcome is recorded as a participant count. Target lesions were to be assessed through tumor imaging, with the description naming CT scan, MRI, and/or chest x-ray at 3-5 weeks after induction chemotherapy. The response criteria are identified as RECIST v1.0; the accompanying definition describes complete response as disappearance of all target lesions and partial response as a decrease of at least 30% in the sum of the longest diameters of target lesions. The criteria description refers to assessment by MRI.

Response is used as an early measure of tumor change after treatment. A count of participants meeting the response criteria can summarize how many had a documented complete or partial response at the specified assessment. It does not, by itself, describe response durability, survival, toxicity, or quality of life. Those are distinct outcomes and should not be inferred from a response endpoint.

The registry record does not report the observed number of responders, the total number included in the endpoint analysis, or an estimated response rate with uncertainty. Thus, the endpoint definition is available, but its result and precision cannot be evaluated from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods can clarify what an endpoint means and what kinds of conclusions a design can support. In this study, however, the registry record does not report an analysis plan or outcome analysis records. The distinctions below describe general statistical concepts; they should not be read as methods confirmed to have been used for this study.

What does a single-group design estimate?

In general, a single-group study can describe an outcome among the participants who received the study strategy. For a binary response outcome, each participant can be classified as meeting or not meeting the response definition, and the response count or proportion can then be reported for a clearly specified analysis population. Without a concurrent comparator, this estimate is not a randomized estimate of the difference between two treatments. It describes the observed group and can be affected by who enrolled, which participants were assessed, and how the outcome was measured.

The registry record identifies the primary outcome as a participant count, but does not report the number included in the response analysis or the number with a response. It therefore does not give the information needed to evaluate an observed response proportion. Enrollment alone cannot establish how many participants completed imaging or had an evaluable endpoint.

How should uncertainty be understood?

General statistical explanation: a confidence interval expresses uncertainty around an estimate under a specified statistical method and its assumptions. For a binary outcome, an interval around a response proportion can indicate how precisely the data estimate that proportion. A count without an analysis denominator, or a rate without an interval, gives less information about precision. No confidence interval for the primary endpoint is reported in the registry record, and no primary response estimate is reported at all.

For a single-group result, an interval would address uncertainty in the group’s outcome estimate; it would not remove the design limitation that there is no randomized comparison. Precision and causal interpretation are different issues. A narrow interval, if one were reported, would not by itself show that the treatment strategy caused an outcome or outperformed another strategy.

What does the response definition contribute?

The endpoint uses RECIST v1.0 criteria and defines response as complete or partial response. These rules make the outcome more explicit than an unstructured judgment, because they specify what kinds of imaging changes count. The description identifies the assessment as imaging-based and places it 3-5 weeks after induction chemotherapy, within the 11-week outcome timeframe. It names CT scan, MRI, and/or chest x-ray in the assessment description, while the criteria text refers to assessment by MRI. The registry record does not clarify how imaging modality was selected or how any differences in assessment were handled.

General statistical explanation: a prespecified outcome definition and assessment time help make an estimate interpretable. If assessment timing, measurement, or evaluability varies, those features can affect which observations enter the endpoint analysis. The registry record does not report how missing or unevaluable imaging assessments were handled, so no missing-data approach can be attributed to this study.

Why is the treatment sequence relevant to interpretation?

The intervention is a sequence, not a single isolated component: induction chemotherapy is followed by transoral surgery, with subsequent care based on post-surgical risk category. An overall response assessment after induction chemotherapy concerns response at that stage of the sequence. It should not be treated as a direct measure of the effect of surgery or of later radiation or chemotherapy. Since there is no control group, the separate contribution of each component cannot be estimated from a simple group-level outcome. The record does not report an analysis designed to separate component effects.

What do the planning assumptions mean?

General statistical explanation: sample-size planning calculations describe how many participants or events a hypothetical study might need under stated assumptions. They are planning illustrations, not observed outcomes, and they are not observed power. The registry record’s stated planning assumptions refer to a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a fraction of an observed effect; time-to-event illustrations use a total event count, while other illustrations use participants per arm. Those assumptions describe planning illustrations and do not convert this single-group study into a two-arm randomized comparison. No numerical sample-size illustration is reported in the registry record, and no trial-specific sample-size justification is reported.

General statistical explanation: over-dispersion matters when observed variability is greater than a chosen model expects, because standard errors and uncertainty estimates can then be too small if the model is not appropriate. The primary endpoint is defined as a binary response count, but the registry record does not report a model or an analysis method. It would therefore be inappropriate to claim that over-dispersion was assessed or that any particular model was used.

In sum, the available record supports explanation of the endpoint and design, but not reconstruction of the statistical analysis. The analysis population, missing-data handling, uncertainty estimates, analysis model, and trial-specific planning rationale are not reported in the registry record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Induction Chemotherapy Followed by Transoral Surge")
n      <- c(40)
events <- c(37)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Induction Chemotherapy Followed by Transoral Surge  40  37  92.5  79.6  98.4  80.1  97.4  80.1  97.3

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists the primary endpoint as overall response rate and names 12 outcome measures overall. The secondary outcomes include feasibility, risk-level change after induction chemotherapy, overall survival, progression-free survival, voice and swallowing measures, pathologic complete response, and response at the primary site. Listing several outcomes raises a general statistical issue: when many outcomes are tested, the chance of at least one apparently unusual result can increase if each is assessed separately. This is a general concern, not evidence that any particular testing procedure was used in this study.

A multiplicity strategy, such as a prespecified hierarchy or adjustment, is not reported in the registry record. Nor is a statistical analysis plan reported. The record gives no outcome analysis entries, so there are no reported test results from which to assess whether any adjustment was applied. It is also not reported whether the listed outcomes were all confirmatory, exploratory, or subject to a defined order of testing.

The record does not report the number of participants included in each endpoint analysis, the handling of missing observations, or the rules for defining evaluable participants. This matters because enrollment does not necessarily equal the analysis population for an imaging-based endpoint or a follow-up outcome. No imputation, censoring, or other missing-data procedure can be inferred from the outcome descriptions alone. The analysis populations for response, survival, function, and safety are not reported in the registry record.

Accordingly, the outcome list identifies what the study planned to measure, but does not establish which measures were analyzed, how missing values were handled, or how conclusions were protected against multiple testing.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: diarrhea (5.0%), febrile neutropenia (5.0%), neutrophil count decreased (5.0%), chest pain - cardiac (2.5%), confusion (2.5%).

The registry record reports safety counts for the group titled Induction Chemotherapy Followed by Transoral Surgery. Serious adverse events were recorded for 7 of the 40 participants at risk. Other adverse events were recorded for 39 of the 40 participants at risk, and 1 death was recorded. These are distinct registry counts; they should not be combined into a new total, since the record does not clarify overlap among participants or categories.

The listed serious-event terms include diarrhea, febrile neutropenia, and decreased neutrophil count, each reported as 5.0%. Chest pain - cardiac, confusion, and dehydration are each reported as 2.5%. The percentages are reproduced as recorded. They describe listed event categories, not necessarily the number of unique participants, and the record does not state whether one participant could contribute to more than one term.

These figures do not establish that an event was caused by a specific treatment, nor do they provide a comparison with an untreated or alternative-treatment group. The registry record does not report event severity grading beyond the serious versus other grouping in these counts, the observation period for each event, or additional details needed to interpret attribution and duration. The counts should therefore be read as the safety information recorded for this study group, not as a comparative estimate of treatment-related risk.

13. What the Result Does, and Does Not, Mean

The registry record defines an early imaging-based response outcome for a phase 2, single-group treatment strategy, and reports safety counts for the study group. It does not report the observed primary response count or rate, or analysis results for the listed secondary outcomes. The central efficacy result is therefore unavailable in the registry record. Neither the completed status nor the enrollment figure can substitute for an endpoint result.

If response results were available, they would describe the participants assessed under the study’s response definition and at the specified assessment stage. They would not, on their own, show that the treatment strategy caused a response or that it performs better than an alternative. The lack of a comparator is a design limitation for comparative claims, not a finding about whether the strategy is beneficial or harmful.

The treatment approach includes induction chemotherapy, surgery, and risk-guided subsequent care. The primary endpoint is assessed after induction chemotherapy, so it captures an early response measure rather than every contribution or outcome across the full sequence. The registry record also lists survival, feasibility, pathologic response, and voice and swallowing outcomes, but does not report their results. No inference about those outcomes should be drawn from the primary endpoint definition or safety counts.

The safety information indicates that serious and other adverse events were recorded, along with a death. The available figures do not establish event attribution or comparative risk. They are important descriptive observations, but they do not resolve whether a treatment component caused an event or how the safety profile compares with another approach.

In short, the record documents the design, aims, endpoint definitions, enrollment, and some safety counts. It does not provide the response result or analysis details needed to judge the primary outcome’s magnitude and precision. The evidence described in the record should not be stretched into a treatment recommendation or a claim of comparative effectiveness.

14. Why This Trial Matters Statistically

This trial is statistically informative as an example of the distinction between a clearly stated research question and a reported result. The registry record defines overall response rate, gives a response framework, and identifies an assessment period. Yet it does not report the observed response count, the endpoint analysis population, or an uncertainty estimate. A well-defined outcome is necessary for interpretation, but it cannot answer the research question without the corresponding data and analysis.

The design also makes the role of comparison explicit. A single-group study can document outcomes in participants receiving a complex treatment sequence, but it does not create a randomized counterfactual. This distinction matters especially when the intervention has several stages and later care varies according to risk category. An overall outcome for the group cannot isolate the contribution of induction chemotherapy, surgery, or subsequent treatment.

The record’s multiple listed outcomes illustrate why a complete analysis plan matters. Different outcomes address different aspects of the study, and interpreting a collection of tests or estimates requires clarity about which were primary, how missing information was handled, and whether testing procedures were prespecified. Those details are not reported, so readers cannot evaluate the analysis strategy from the registry record.

Finally, the safety counts show why descriptive totals need context. Event categories, timing, overlap, and attribution influence what a count can mean. Without a comparator and further event details, the counts describe reported experience but do not establish comparative risk. The key statistical lesson is to keep endpoint definitions, analysis results, precision, and design limitations separate when interpreting a clinical trial.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting the primary outcome is that the registry record does not report an observed response result. It also does not report the number assessed, the analysis denominator, or an uncertainty estimate. Without those details, neither the response frequency nor its precision can be evaluated. The recorded enrollment of 40 does not establish how many participants contributed to the endpoint analysis.

The non-randomized, single-group design has no concurrent control group. As a result, the record cannot provide a randomized comparison with another treatment strategy. The intervention is multimodality and risk adapted, so group-level outcomes would not by themselves separate the effects of its individual components. The specific post-surgical treatment schedules for low-, medium-, and high-risk categories are not fully described in the registry record.

The outcome description names CT scan, MRI, and/or chest x-ray, while the response-criteria text refers to assessment by MRI. The record does not clarify imaging selection or how assessments across modalities were handled. It also does not report missing-data procedures, endpoint-specific analysis populations, or the statistical model and analysis plan. These omissions limit evaluation of the reliability and reproducibility of any analysis.

The listed serious adverse-event terms provide some detail, but the record does not report enough information to establish attribution, event overlap, or the observation period in the figures. The listed secondary outcomes do not have analysis results in the registry record. These limitations concern what can be interpreted from the record; they should not be mistaken for evidence that an unreported outcome was favorable or unfavorable.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery — NCT01612351.
• Registry record last updated 2026-03-17; status last verified 2026-02.
• Results first posted 2017-10-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01612351 is a completed phase 2, non-randomized, single-group study sponsored by UNC Lineberger Comprehensive Cancer Center. Enrollment was 40. The study began in 2012-06, and primary completion was 2016-11. Masking is listed as none.

The treatment strategy involved induction chemotherapy with carboplatin, paclitaxel, and lapatinib, followed by transoral surgery and risk-guided subsequent care. The primary endpoint was overall response rate, defined as a count of participants with complete or partial response, with an 11-week timeframe and imaging assessment described at 3-5 weeks after induction chemotherapy.

The registry record does not report the observed primary response result or outcome analysis records. It reports serious adverse events for 7 participants among 40 at risk, other adverse events for 39 among 40 at risk, and 1 death. The lack of a comparator and the absence of reported efficacy analyses limit what can be concluded about comparative outcomes.